Literature DB >> 11696365

Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion.

A M Lambeir1, C Durinx, P Proost, J Van Damme, S Scharpé, I De Meester.   

Abstract

Dipeptidyl-peptidase IV (DPPIV/CD26) metabolizes neuropeptides regulating insulin secretion. We studied the in vitro steady-state kinetics of DPPIV/CD26-mediated truncation of vasoactive intestinal peptide (VIP), pituitary adenylyl cyclase-activating peptide (PACAP27 and PACAP38), gastrin-releasing peptide (GRP) and neuropeptide Y (NPY). DPPIV/CD26 sequentially cleaves off two dipeptides of VIP, PACAP27, PACAP38 and GRP. GRP situates between the best DPPIV/CD26 substrates reported, comparable to NPY. Surprisingly, the C-terminal extension of PACAP38, distant from the scissile bond, improves both PACAP38 binding and turnover. Therefore, residues remote from the scissile bond can modulate DPPIV/CD26 substrate selectivity as well as residues flanking it.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11696365     DOI： 10.1016/s0014-5793(01)02982-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  22 in total

1.  What mediates the benefits associated with dipeptidyl peptidase-IV inhibition?

Authors:  B Ahrén
Journal:  Diabetologia       Date:  2005-03-16       Impact factor: 10.122

2.  Decreased neprilysin and pulmonary vascular remodeling in chronic obstructive pulmonary disease.

Authors:  Marilee J Wick; Erica J Buesing; Carol A Wehling; Zoe L Loomis; Carlyne D Cool; Martin R Zamora; York E Miller; Sean P Colgan; Louis B Hersh; Norbert F Voelkel; Edward C Dempsey
Journal:  Am J Respir Crit Care Med       Date:  2010-09-02       Impact factor: 21.405

Review 3.  Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation.

Authors:  K Pabreja; M A Mohd; C Koole; D Wootten; S G B Furness
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

4.  Proline-rich cytokine from neurosecretory granules: a new natural substrate for dipeptidyl peptidase IV.

Authors:  Alvard A Antonyan; Svetlana G Sharoyan; Sona S Mardanyan; Armen A Galoyan
Journal:  Neurochem Res       Date:  2010-09-14       Impact factor: 3.996

5.  Structural and agonist properties of XCL2, the other member of the C-chemokine subfamily.

Authors:  Jamie C Fox; Takashi Nakayama; Robert C Tyler; Tara L Sander; Osamu Yoshie; Brian F Volkman
Journal:  Cytokine       Date:  2014-12-11       Impact factor: 3.861

Review 6.  Dipeptidyl peptidase-4: a key player in chronic liver disease.

Authors:  Minoru Itou; Takumi Kawaguchi; Eitaro Taniguchi; Michio Sata
Journal:  World J Gastroenterol       Date:  2013-04-21       Impact factor: 5.742

7.  Secreted dipeptidyl peptidase IV activity in the dimorphic fungal pathogen Histoplasma capsulatum.

Authors:  Kendal G Cooper; Jon P Woods
Journal:  Infect Immun       Date:  2009-04-06       Impact factor: 3.441

8.  Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation.

Authors:  Kathleen Aertgeerts; Sheng Ye; Mike G Tennant; Michelle L Kraus; Joe Rogers; Bi-Ching Sang; Robert J Skene; David R Webb; G Sridhar Prasad
Journal:  Protein Sci       Date:  2004-01-10       Impact factor: 6.725

9.  Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV.

Authors:  Jais R Bjelke; Jesper Christensen; Per F Nielsen; Sven Branner; Anders B Kanstrup; Nicolai Wagtmann; Hanne B Rasmussen
Journal:  Biochem J       Date:  2006-06-01       Impact factor: 3.857

Review 10.  Lymphocytes are a major source of circulating soluble dipeptidyl peptidase 4.

Authors:  A Casrouge; A V Sauer; R Barreira da Silva; M Tejera-Alhambra; S Sánchez-Ramón; C Cancrini; M A Ingersoll; A Aiuti; M L Albert
Journal:  Clin Exp Immunol       Date:  2018-09-24       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.